Q-omics provides the consensus-scored GNG5P2 profile across patient tissues and cancer cell-line models. GNG5P2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GNG5P2 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, GNG5P2 RNA expression shows 8,470 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, BRCA, and GBM as cancer lineages where GNG5P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNG5P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNG5P2 survival associations across molecular data types. GNG5P2 RNA expression shows survival associations in the most cancer types (20), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNG5P2 RNA expression–survival associations across cancer types. High GNG5P2 expression shows unfavorable associations in KICH, ACC, LGG, DLBC and UCEC, but favorable associations in BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for GNG5P2 RNA expression.
This table summarizes GNG5P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 2. The strongest signals are observed in BRCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GNG5P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNG5P2 shows lower tumor expression in CHOL, LIHC and PAAD and higher tumor expression in BRCA, KICH and UCEC. The BRCA box plot shows higher GNG5P2 RNA expression in tumor versus normal tissue (log2 FC = +0.219, t-test p < 0.001).
This table shows molecular features associated with GNG5P2 in patient tissues and cancer cell lines. In patient samples, GNG5P2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
